The design rationale for these compounds was to merge the 4-chlorophenyltetrahydroquinoline moiety for AChE inhibition with the pyrazole and thiourea moieties of known COX-2 inhibitors (e.g., celecoxib) to potentially modulate the ACh and ROS/inflammatory aspects of AD. This evidence concerns the gene ACHE and Alzheimer disease.